WHAT WE WANT
IF ACCESS TO MEDICINES IS BROKEN, WE MUST FIX IT.
Universal access to medicines cannot be a luxury available to only an elite few. We have the opportunity to build an efficient and sustainable medical research system that guarantees the universal right to health and ensures access to the medicines people need at an affordable price.
HOW ARE WE GOING
TO OBTAIN IT?
TRANS
PAREN
CY
With an informed public debate and the introduction of transparency system-wide in order to know: the actual transaction prices of medicine purchases; public investments and tax incentives for R&D that result in marketed technologies; clinical data, research results and costs of pharmaceutical products financed with public funds.
PUBLIC
INTEREST
CRITERIA
With criteria that affect the final price of the products, patient access to those and ownership of the innovation itself for all investments made by the State.
NEW
INNOVATION
MODELS
With governments, institutions and research centers promoting R&D initiatives based on new models for medical research and development that do not rely exclusively on patents as an incentive and business model.
